7 Major Markets Stargardt Disease (STGD) Epidemiology Forecasts Report 2020-2024 & 2034: Focus on United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Stargardt Disease (STGD) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

The report delivers an in-depth understanding of STGD, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Stargardt epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases, onset-age specific cases, type-specific cases, symptom-specific and treated cases in the United States, EU4 countries (Germany, France, Italy, Spain), and the United Kingdom, and Japan from 2020 to 2034.

In the 7MM, the United States accounted for the highest number of diagnosed prevalent cases of Stargardt, which is 43.0% of the diagnosed-incident cases of Stargardt in 2023. In the US, out of all age groups, the highest onset age-specific cases accounted for >20 years, followed by 20-39 years in 2020. In contrast, the least onset age-specific cases were observed in =60 years age groups.

Among the EU4 and the UK, Germany accounted for the highest number of Stargardt Disease cases, followed by the UK, whereas Spain accounted for the lowest number of prevalent cases. In Japan, the highest symptoms-specific cases of Symptomatic Stargardt Disease were for reduced vision, followed by Nyctalopia, Photophobia, and other cases, respectively, in 2023.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of STGD, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Key Highlights

• Stargardt disease, also known as Stargardt's macular dystrophy or juvenile macular degeneration, stands out as the most prevalent form of macular degeneration in children, estimated to affect approximately 10-12.5 per 100,000 individuals in the United States.
• Stargardt (STGD1) is a genetic disorder primarily caused by autosomal recessive homozygous or compound heterozygous mutations in the ABCA4 gene. These mutations accelerate lipofuscin accumulation in the retinal pigment epithelium.
• Age of onset is a surrogate marker: The earlier the onset, the more severe the disease course. Onset usually occurs in childhood or early adolescence, at about 10-15 years of age.
• Stargardt disease is characterized by central vision loss, evident in color fundus photography showing macular atrophy with yellow-white lipofuscin flecks at the retinal pigment epithelium level.
• Diagnostic evaluation of Stargardt disease is based on family history, visual acuity, fundus examination, visual field testing, fluorescein angiography, fundus autofluorescence (FAF), electroretinography (ERG), and optical coherence tomography (OCT).
• In 2023, the United States accounted for the highest number of Stargardt disease cases, which is 43.0% of the diagnosed-prevalent cases of Stargardt disease in the 7MM.
• Among the EU4 and the UK, out of all symptoms of Stargardt disease, the highest cases accounted for reduced vision, followed by Nyctalopia, Photophobia, and others in 2023.
• Apart from the lack of appropriate treatment options, heterogeneity of the disease, diagnostic challenges, and lack of prevalence knowledge are some of the other notable unmet needs associated with Stargardt disease.

STGD Report Insights

• Patient Population
• Total diagnosed prevalent cases of STGD, onset age-specific cases, symptom-specific cases, type-specific cases, and total diagnosed cases of STGD
• Country-wise Epidemiology Distribution

STGD Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage
• STGD Epidemiology Segmentation

STGD Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Stargardt Disease Market Overview at a Glance

3.1. Patient Share (%) Distribution in 2023

3.2. Patient Share (%) Distribution in 2034

4. Executive Summary of Stargardt Disease

5. Key Events

6. Disease Background and Overview

6.1. Introduction

6.2. Cause of Stargardt Disease

6.3. Clinical Representation of Stargardt Disease

6.4. Pathophysiology of Stargardt Disease

6.5. Classification of Stargardt Disease

6.6. Diagnosis

7. Methodology

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Assumptions and Rationale

8.3. Diagnosed Prevalent Cases of Stargardt Disease in the 7MM

8.4. The United States

8.4.1. Diagnosed Prevalent Cases of Stargardt Disease in the United States

8.4.2. Onset Age-specific Cases of Stargardt Disease in the United States

8.4.3. Type-specific Cases of Stargardt Disease in the United States

8.4.4. Symptom-specific Cases of Symptomatic Stargardt Disease in the United States

8.4.5. Treated Cases of Stargardt Disease in the United States

8.5. EU4 and the UK

8.6. Japan

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/k8izyf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.